Immunome, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -51.3% | -51.3% | -42.7% |
| FY2022 | -221.6% | -221.6% | -153.4% |
| FY2023 | -89.1% | -89.1% | -71.9% |
| FY2024 | -161.7% | -161.7% | -121.9% |
| FY2025 | -33.5% | -33.5% | -31.1% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -51.3% | -51.3% | -42.7% |
| FY2022 | -221.6% | -221.6% | -153.4% |
| FY2023 | -89.1% | -89.1% | -71.9% |
| FY2024 | -161.7% | -161.7% | -121.9% |
| FY2025 | -33.5% | -33.5% | -31.1% |